Suppr超能文献

亚微米可分散游离植物甾醇对非酒精性脂肪性肝病的疗效:一项初步研究。

Efficacy of Submicron Dispersible Free Phytosterols on Non-Alcoholic Fatty Liver Disease: A Pilot Study.

作者信息

Brañes María C, Gillet Raimundo, Valenzuela Rodrigo

机构信息

Naturalis Research Consortium, Santiago 8700548, Chile.

Department of Nutrition, Faculty of Medicine, University of Chile, Santiago 8380000, Chile.

出版信息

J Clin Med. 2023 Jan 27;12(3):979. doi: 10.3390/jcm12030979.

Abstract

BACKGROUND

No pharmacological treatment is yet approved for non-alcoholic fatty liver disease (NAFLD). Plant sterols have shown healthy properties beyond lowering LDL-cholesterol, including lowering triglycerides and lipoprotein plasma levels. Despite pre-clinical data suggesting their involvement in liver fat control, no clinical study has yet been successful.

AIMS

Testing a sub-micron, free, phytosterol dispersion efficacy on NAFLD.

METHODS

A prospective, uncontrolled pilot study was carried out on 26 patients with ≥17.4% liver steatosis quantified by magnetic resonance imaging. Subjects consumed daily a sub-micron dispersion providing 2 g of phytosterols. Liver fat, plasma lipids, lipoproteins, liver enzymes, glycemia, insulinemia, phytosterols, liposoluble vitamins and C-reactive protein were assessed at baseline and after one year of treatment.

RESULTS

Liver steatosis relative change was -19%, and 27% of patients reduced liver fat by more than 30%. Statistically and clinically significant improvements in plasma triglycerides, HDL-C, VLDL and HDL particle number and C-reactive protein were obtained, despite the rise of aspartate aminotransferase, glycemia and insulinemia. Though phytosterol plasma levels were raised by >30%, no adverse effects were presented, and even vitamin D increased by 23%.

CONCLUSIONS

Our results are the first evidence in humans of the efficacy of submicron dispersible phytosterols for the treatment of liver steatosis, dyslipidemia and inflammatory status in NAFLD.

摘要

背景

目前尚无药物治疗被批准用于非酒精性脂肪性肝病(NAFLD)。植物甾醇已显示出除降低低密度脂蛋白胆固醇之外的健康益处,包括降低甘油三酯和脂蛋白血浆水平。尽管临床前数据表明它们参与肝脏脂肪控制,但尚无临床研究取得成功。

目的

测试亚微米级游离植物甾醇分散体对NAFLD的疗效。

方法

对26例经磁共振成像量化肝脏脂肪变性≥17.4%的患者进行了一项前瞻性、非对照的试点研究。受试者每天服用提供2克植物甾醇的亚微米分散体。在基线和治疗一年后评估肝脏脂肪、血脂、脂蛋白、肝酶、血糖、胰岛素血症、植物甾醇、脂溶性维生素和C反应蛋白。

结果

肝脏脂肪变性相对变化为-19%,27%的患者肝脏脂肪减少超过30%。尽管天冬氨酸转氨酶、血糖和胰岛素血症有所升高,但血浆甘油三酯、高密度脂蛋白胆固醇、极低密度脂蛋白和高密度脂蛋白颗粒数量以及C反应蛋白在统计学和临床上均有显著改善。虽然植物甾醇血浆水平升高>30%,但未出现不良反应,甚至维生素D增加了23%。

结论

我们的结果首次在人体中证明了亚微米级可分散植物甾醇对治疗NAFLD中的肝脏脂肪变性、血脂异常和炎症状态的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab39/9918217/3e46e9265c0f/jcm-12-00979-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验